Whole-Brain Spectroscopy Guided Personalized Delivery of Tumor Treating Fields in Glioblastoma Patients
Enrolling By Invitation
22-99 years
All
Phase
N/A
155 participants needed
1 Location
Brief description of study
The research study is for Glioblastoma (GBM) patients beginning Optune, a therapy that uses - tumor treating fields (TTFields).
As a part of this study participants will either receive Optune with standard treatment array mapping from MR imaging or an alternative treatment array mapping based on advanced MR imaging also known as whole brain spectroscopy. Whole brain spectroscopy provides additional information on the makeup of the tissue within the brain, identifying certain metabolites that are present in cancer cells versus healthy tissue. The arrays are the pads that stick directly to the scalp and are connected with wires to the Optune device. TTFields are transmitted to through the array location.
In this study participants will either receive a standard Optune array mapping treatment plan or an alternative Optune array mapping treatment plan that focuses TTFields based on your advanced MR imaging. The hypothesis is that the study will show that the alternative array mapping improves Optune treatment.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: glioblastoma,tumor
-
Age: Between 22 Years - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 848715
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
